INNOVUS PHARMACEUTICALS, INC. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - May 12, 2017

Attached files

file filename
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - INNOVUS PHARMACEUTICALS, INC.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - INNOVUS PHARMACEUTICALS, INC.ex31-1.htm
10-Q - FORM 10-Q - INNOVUS PHARMACEUTICALS, INC.innv10q_mar312017.htm
 
Exhibit 32.1
 
CERTIFICATION REQUIRED BY
SECTION 1350 OF TITLE 18 OF THE UNITED STATES CODE
 
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned hereby certifies in his capacity as the specified officer of Innovus Pharmaceuticals, Inc. (the “Company”), that, to the best of his knowledge, the Quarterly Report of the Company on Form 10-Q for the fiscal quarter ended March 31, 2017 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.
 
Date: May 15, 2017
 
 
 
/s/ Bassam Damaj
 
Bassam Damaj, Ph.D.
President, Chief Executive Officer and Director
 
(Principal Executive Officer)
  
 
Date: May 15, 2017
 
 
 
/s/ Rauly Gutierrez
 
Rauly Gutierrez, CPA
Vice President, Finance
 
(Principal Financial Officer)
  
 
This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
 
 
 
 
 

INNOVUS PHARMACEUTICALS, INC. Reports